Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Wilkin

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Plos One|May 8, 2014
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)John E McKinnon, Robbie B Mailliard, Susan Swindells, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivityTimothy J Wilkin, Mathew Bidwell Goetz, Robert Leduc, et al.
The Journal of Infectious Diseases|June 29, 2012
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256Timothy J Wilkin, Christina M Lalama, John McKinnon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2007
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, et al.
The Journal of Infectious Diseases|October 31, 2009
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211Zhaohui Su, Roy M Gulick, Amy Krambrink, et al.
Plos One|December 27, 2018
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305Shashi N Kapadia, Chunyuan Wu, Kenneth H Mayer, et al.
Contemporary Clinical Trials|January 12, 2022
Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIVJeannette Y Lee, Shelly Y Lensing, J Michael Berry-Lawhorn, et al.
The Lancet. HIV|October 2, 2015
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trialChad J Achenbach, Lambert Assoumou, Steven G Deeks, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
The Journal of Antimicrobial Chemotherapy|November 18, 2021
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305Todd T Brown, Krista Yuhas, Kenneth H Mayer, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Plos One|May 8, 2014
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)John E McKinnon, Robbie B Mailliard, Susan Swindells, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivityTimothy J Wilkin, Mathew Bidwell Goetz, Robert Leduc, et al.
The Journal of Infectious Diseases|June 29, 2012
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256Timothy J Wilkin, Christina M Lalama, John McKinnon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2007
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, et al.
The Journal of Infectious Diseases|October 31, 2009
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211Zhaohui Su, Roy M Gulick, Amy Krambrink, et al.
Plos One|December 27, 2018
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305Shashi N Kapadia, Chunyuan Wu, Kenneth H Mayer, et al.
Contemporary Clinical Trials|January 12, 2022
Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIVJeannette Y Lee, Shelly Y Lensing, J Michael Berry-Lawhorn, et al.
The Lancet. HIV|October 2, 2015
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trialChad J Achenbach, Lambert Assoumou, Steven G Deeks, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
The Journal of Antimicrobial Chemotherapy|November 18, 2021
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305Todd T Brown, Krista Yuhas, Kenneth H Mayer, et al.
Pageof 7